The French Medicinal Chemistry Society (Société de Chimie Thérapeutique - SCT) is pleased to invite you to Toulouse (Midi-Pyrénées) on July 5-7, 2017 for the 53rd edition of the International Conference on Medicinal Chemistry (RICT 2017).
The congress will be devoted to “Drug Discovery & Selection” and the main topics will be:
It is noteworthy to point out that this is the first time since 1992 that the RICT are organised in Toulouse. In that respect the event is particularly important for the City and Metropole of Toulouse, but also for the Region Languedoc Roussillon Midi-Pyrénées and all partners from University, CNRS, INSERM, pharmaceutical companies and others. With the emergence of Oncopôle Toulouse and important Regional scientific platforms like GALA, PICT, Metabolomics, Toulouse White Biotechnology, new opportunities and new partnerships are emerging in the domain of Chemistry/Biology/Health, based on the exceptional expertise and knowledge of Toulouse’s laboratories of the academic and private sector.
RICT 2017 will greatly contribute to a higher visibility of the Region towards the new challenges and thus, help to structure and strengthen the Research, Innovation and Development in the domain of “Drug Discovery & Selection”.
It is also important to point out that RICT 2017 have received the label of the EuroScience Open Forum “ESOF 2018 - Toulouse European City of Science”.
As for previous editions of RICT, the scientific committee will ensure the high quality and diversity of the scientific programme together with the accessibility of the meeting to PhD/post-doc and local Master students. For the latter, an advantageous registration fee is proposed. Moreover, a special career session will be organised with industrial and academic participants.
During the meeting the P. Ehrlich Lecture Prize of the ‘Société de Chimie Thérapeutique’ will be awarded to a researcher or a research team for his or her outstanding contributions to medicinal chemistry. Furthermore, the Pierre Fabre Award for Therapeutic Innovation will be attributed to a researcher having accomplished a decisive action or made a discovery contributing to a therapeutic innovation. In addition, a poster session will provide the opportunity for all participants to present their current results. “Best poster” prizes will be attributed at the end of the meeting.